Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Gastroenterology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Int J Cancer. 2020 Aug 15;147(4):1098-1106. doi: 10.1002/ijc.32839. Epub 2020 Jan 9.
The Dutch colorectal cancer (CRC) screening program started in 2014, inviting the target population biennially to perform a fecal immunochemical test (FIT). We obtained prospectively collected data from the national screening information-system to present the results of the second round (2016) and evaluate the impact of increasing the FIT cut-off halfway through the first round from 15 to 47 μg Hb/g feces on outcomes in the second round. Second round screening was done with a 47 μg Hb/g feces FIT cut-off. Participants were classified based on first round participation status as either FIT (15,47) or FIT (47,47) participants, and previous nonparticipants. In total, 348,891 (75.9%) out of 459,740 invitees participated in the second round. Participation rates were 93.4% among previous participants and 21.0% among previous non-participants. FIT(47,47) participants had a significantly higher detection rate of AN (15.3 vs. 10.4 per 1,000 participants) compared to FIT(15,47) participants in the second round, while their cumulative detection rate of AN over two rounds was significantly lower (45.6 vs. 52.6 per 1,000 participants). Our results showed that participation in the Dutch CRC screening program was consistently high and that second round detection rates depended on the first round FIT cut-off. The cumulative detection over two rounds was higher among FIT(15,47) participants. These findings suggest that a substantial part of, but not all the missed findings in the first round due to the increased FIT cut-off were detected in the subsequent round.
荷兰结直肠癌(CRC)筛查计划于 2014 年启动,每两年邀请目标人群进行一次粪便免疫化学测试(FIT)。我们从国家筛查信息系统中获得了前瞻性收集的数据,以呈现第二轮(2016 年)的结果,并评估在第一轮中途将 FIT 截止值从 15 增加到 47μg Hb/g 粪便对第二轮结果的影响。第二轮筛查使用 47μg Hb/g 粪便 FIT 截止值。参与者根据第一轮参与情况分为 FIT(15,47)或 FIT(47,47)参与者以及以前的非参与者。在总共 459,740 名受邀者中,有 348,891 人(75.9%)参加了第二轮。以前参与者的参与率为 93.4%,以前非参与者的参与率为 21.0%。与第二轮中的 FIT(15,47)参与者相比,FIT(47,47)参与者的 AN 检测率(每 1000 名参与者中有 15.3 例)显著更高,而他们在两轮中的累积 AN 检测率(每 1000 名参与者中有 45.6 例)显著更低。我们的结果表明,荷兰 CRC 筛查计划的参与率一直很高,第二轮的检测率取决于第一轮的 FIT 截止值。两轮累积检测率在 FIT(15,47)参与者中更高。这些发现表明,由于 FIT 截止值增加而在第一轮中错过的部分但不是全部发现,在随后的一轮中被检测到。